AXIM is a major investment of Medical Marijuana, Inc. (OTC PINK: MJNA), the first publicly traded cannabis company
REDONDO BEACH, CA–(Marketwired – Jun 27, 2017) – SECFilings.com, a leading financial news and information portal offering free real time public company filing alerts, announces the publication of an article covering AXIM® Biotechnologies Inc. (OTCQB: AXIM) and its recent patent on cannabinoid and opioid combinations in chewing gum. Medical Marijuana Inc. (OTC PINK: MJNA), the first publicly traded cannabis company, holds about 22.7 million shares of AXIM Biotech stock.
More than 12.5 million people misuse prescription opioids, according to the U.S. Department of Health and Human Services, while two million people have been formally diagnosed with an addiction. These addictions cause $78.5 billion in economic damages each year and lead to more than 33,000 deaths from overdose each year. Despite these issues, physicians have few alternatives for prescribing opioids for pain management.
New Patent Addition
AXIM Biotechnologies recently announced a patent on chewing gum with a controlled release of cannabinoids and opioid agonists and/or antagonists for addiction and/or dependence treatment. In addition, the same chewing gum formulation may be used for the treatment of chronic pain as an alternative to opioid-only treatment options, which could represent an enormous end market for future product lines.
“Opioid addiction is a serious global problem that affects the health, social, and economic welfare of all societies,” said AXIM Biotech CEO Dr. George E. Anastassov, MD, DDS, MBA. “Opioid addiction therapy depends on a variety of techniques. One of them is the replacement therapy, where an opioid is replaced with another less potent and less addictive opioid that curbs the cravings and reduces withdrawal symptoms.”
There is evidence that cannabinoids — and cannabidiol (CBD) in particular — may decrease cravings for narcotics. The company aims to provide these cannabinoids in microencapsulated form, which may improve its chewing gum’s taste, prevent binding with the gum’s base, control release during mastication (chewing), and further improve the bioavailability of the cannabinoids once entering the gastrointestinal tract.
Opioid addiction is often chemically treated using a combination of two approaches. First, agonists like methadone or buprenorphine activate opioid receptors in the brain to produce a substitute opioid effect with less potential for addiction. Second, antagonists like naltrexone and naloxone block opioids by attaching to the same opioid receptors without activating them, which reduces the side effects of the agonists and reducing addiction over time.
The addition of cannabinoids to this treatment strategy could prove to be a breakthrough because cannabinoids may help with pain management. Often times, a large struggle with overcoming an opioid addiction is dealing with the resulting increase in pain from the reduction in opioid consumption. Cannabinoids can help fill the void in a way that avoids any addictive properties and enhances the overall patient wellbeing.
These same properties mean that cannabinoids may be able to act as an opioid substitute in first-line pain medications. For instance, a patient that would normally take 100% opioids may be able to take just 50% opioids and 50% cannabinoids, reducing the likelihood of an opioid addiction and the other negative side effects associated with high levels of opioids. This may be particularly impactful in cases of chronic pain management.
The company’s other clinical programs include chewing gum formulations for prescription and over-the-counter indications, as well as topical applications, suppositories, and ophthalmic preparations. Its CanChew Plus® and AX-1602 represent its most advanced programs that are heading into POC Phase 2A clinical trials in Irritable Bowel Syndrome and Psoriasis — two multi-billion dollar markets that are ripe for innovation.
Please follow the link to read the full article: http://analysis.secfilings.com/articles/181-axim-biotechnologies-otcqb-axim-takes-on-opioid-epidemic-with-new-patent
Founded in 2004, SECFilings.com provides free real time filing alerts to over 600,000 registered members and offers services to help public companies grow their audience of interested investors.
Except for the historical information presented herein, matters discussed in this release contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. Emerging Growth LLC, which owns SECFilings.com, is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. Emerging Growth LLC may from time to time have a position in the securities mentioned herein and may increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice. Emerging Growth LLC may be compensated for its services in the form of cash-based compensation or equity securities in the companies it writes about, or a combination of the two. For full disclosure please visit: http://secfilings.com/Disclaimer.aspx.